The IBC Review of IRB and IACUC Protocols
F6.1 - DU Policy Document 9/1/2006
|
The IBC Review of IRB and IACUC Protocols F6.1 - DU Policy Document 9/1/2006 PURPOSE To describe procedures for the coordination between Institutional Biosafety Committee (IBC) and protocols submitted to the Institutional Review Board for the Protection of Human Subjects in Research (IRB) and the Institutional Animal Care and Use Committee (IACUC) involving recombinant DNA, human pathogens, and/or human samples (tissues or fluids). These protocols will require IBC approval before they are initiated to ensure they are carried out in accordance with NIH and CDC guidelines. DEFINITIONS Recombinant DNA: (sometimes referred to as rDNA) is an artificial DNA sequence resulting from the combining of two other DNA sequences. This includes the engineered introduction of any DNA sequences from one species into cells of another. Human Pathogens: is a biological agent that causes disease or illness to its human host. Bodily fluids: are found in the bodies of human beings and animals. They include fluids that are excreted or secreted from the body as well as fluids that normally are not. Human or Animal Tissues: Any animal or human tissue extracted from or maintained independently in cell culture. POLICY The Institutional Biosafety Committee (IBC), the Institutional Review Board (IRB) and the Institutional Animal Care and Use Committee (IACUC) are committed to ensuring the protection of human and animal subjects involved in research. The IBC will review protocols passed on by the IACUC and the IRB involving recombinant DNA, human or animal tissue/bodily fluids and/or pathogenic organisms to ensure that relevant IBC protocols have been applied for, and approved, before research is initiated. It is the responsibility of the PI to insure they are in compliance with IRB or IACUC and IBC. If the PI anticipates the use of recombinant DNA and/or pathogenic organisms s/he should submit concurrently to the IBC and IRB or IACUC. However, some experiments needing IBC review may not need IACUC or IRB review. In this case, the PI should submit a protocol to IBC independent of any IACUC or IRB protocol. Failure to abide with this policy may result in research misconduct or non-compliance. ROLES AND RESPONSIBILITIES Principal Investigator is responsible for submitting concurrent protocols and ensures they are in compliance with IRB, IACUC and IBC. IRB and IACUC Committee Chairs shall forward any protocols that may need review by the IBC and vice versa; the IBC should forward protocols to the IRB or IACUC for review if necessary. Committee Administrator shall forward each protocol to the appropriate Committee, upon receiving final protocol/proposal for submittal to Committee review. Office of Research and Sponsored Programs (ORSP) serves as the primary liaison for ensuring coordination between the IBC, IRB, and IACUC with respect to protocol review. PROCEDURES
|
|
Office of Research and Sponsored Programs: 2199 S. University Blvd., 222 MRB, Mail Stop 4820 - Denver, CO 80208-4820 Telephone: 303.871.2121 - FAX: 303.871.2623 - E-mail: orsp@du.edu University of Denver - Copyright © 2008 |